---
title: "Nanobiotix: Platform Expansion Potential and Risk-Adjusted NBTXR3 Valuation Support Buy Rating"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283702589.md"
description: "Analyst Swayampakula Ramakanth from H.C. Wainwright has maintained a Buy rating on Nanobiotix with a price target of €34.00. His recommendation is based on the company's emerging platform potential and core asset value, particularly highlighting new preclinical findings related to Nanoprimer technology. Ramakanth's analysis includes a risk-adjusted net present value assessment of NBTXR3 revenue prospects and emphasizes upcoming clinical milestones and the manufacturing transfer to Johnson & Johnson as key value drivers, while also noting various risks for investors to consider."
datetime: "2026-04-22T16:45:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283702589.md)
  - [en](https://longbridge.com/en/news/283702589.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283702589.md)
---

# Nanobiotix: Platform Expansion Potential and Risk-Adjusted NBTXR3 Valuation Support Buy Rating

Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Nanobiotix and keeping the price target at €34.00.

### Claim 30% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Swayampakula Ramakanth has given his Buy rating due to a combination of factors tied to Nanobiotix’s emerging platform potential and core asset value. He highlights new preclinical findings showing that the company’s Nanoprimer technology can enhance systemic exposure and reduce liver uptake for a wide range of therapeutic modalities, suggesting it could evolve into a broadly applicable delivery platform with future clinical development planned around 2027.

In addition, Ramakanth bases his recommendation on a risk-adjusted net present value assessment of NBTXR3 revenue prospects, incorporating conservative assumptions on discount and terminal growth rates while also factoring in the company’s cash position. He underscores forthcoming clinical milestones in multiple oncology indications and the manufacturing transfer to Johnson & Johnson as value drivers, while acknowledging execution, clinical, commercial, financial, partnership, and intellectual property risks that investors should monitor.

### Related Stocks

- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)
- [NBTX.US](https://longbridge.com/en/quote/NBTX.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)

## Related News & Research

- [Nanobiotix Reports Promising Phase 2 Data for NBTXR3 in Stage 3 Inoperable Lung Cancer](https://longbridge.com/en/news/286776980.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Nano One Reports Q1 2026 Results and Reminds Shareholders of Upcoming AGM | NNOMF Stock News](https://longbridge.com/en/news/286480856.md)
- [Could NANO Nuclear (NNE) Construction Permit Move Reframe Its Path From R&D Story To Deployment?](https://longbridge.com/en/news/286786128.md)
- [Nano Nuclear Energy Eyes 2027 Build Amid Rising Costs](https://longbridge.com/en/news/286626080.md)